Sun Pharma Advanced Research Company Ltd.
https://www.sparc.life/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sun Pharma Advanced Research Company Ltd.
India's SPARC Keeps Paclitaxel Ambition Burning For Now
A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.
Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week
The latest drug development news and highlights from our US FDA Performance Tracker.
China Beckons: Sun Joins Indian Firms Priming For Larger Presence
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs